Leerink Partnrs Has Pessimistic View of SLDB Q1 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Stock analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for shares of Solid Biosciences in a research note issued to investors on Thursday, January 9th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.81) per share for the quarter, down from their previous estimate of ($0.80). The consensus estimate for Solid Biosciences' current full-year earnings is ($2.85) per share. Leerink Partnrs also issued estimates for Solid Biosciences' Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($3.17) EPS and FY2026 earnings at ($2.98) EPS.

Several other equities analysts have also commented on the company. Chardan Capital reiterated a "buy" rating and issued a $15.00 target price on shares of Solid Biosciences in a research note on Monday, November 11th. Truist Financial assumed coverage on shares of Solid Biosciences in a report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 target price for the company. JMP Securities initiated coverage on shares of Solid Biosciences in a research note on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price target on the stock. Citizens Jmp raised shares of Solid Biosciences to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Solid Biosciences in a report on Friday. Nine investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $15.30.

Solid Biosciences Stock Down 10.1 %

Shares of NASDAQ:SLDB traded down $0.37 during trading on Monday, reaching $3.31. The stock had a trading volume of 553,034 shares, compared to its average volume of 816,412. Solid Biosciences has a fifty-two week low of $3.28 and a fifty-two week high of $15.05. The business has a fifty day moving average price of $4.88 and a 200-day moving average price of $6.61. The stock has a market cap of $132.25 million, a P/E ratio of -1.09 and a beta of 2.05.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.12).

Institutional Investors Weigh In On Solid Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of SLDB. Vestal Point Capital LP raised its position in shares of Solid Biosciences by 5.1% during the 3rd quarter. Vestal Point Capital LP now owns 2,800,000 shares of the company's stock worth $19,516,000 after purchasing an additional 135,000 shares during the period. Millennium Management LLC increased its holdings in shares of Solid Biosciences by 135.7% in the 2nd quarter. Millennium Management LLC now owns 1,728,065 shares of the company's stock worth $9,798,000 after acquiring an additional 994,984 shares during the period. Point72 Asset Management L.P. lifted its position in Solid Biosciences by 292.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company's stock valued at $3,088,000 after purchasing an additional 330,234 shares during the last quarter. State Street Corp boosted its stake in Solid Biosciences by 9.2% during the 3rd quarter. State Street Corp now owns 441,540 shares of the company's stock valued at $3,078,000 after purchasing an additional 37,130 shares during the period. Finally, Renaissance Technologies LLC grew its position in Solid Biosciences by 303.6% in the 2nd quarter. Renaissance Technologies LLC now owns 277,564 shares of the company's stock worth $1,574,000 after purchasing an additional 208,793 shares during the last quarter. Institutional investors and hedge funds own 81.46% of the company's stock.

Insiders Place Their Bets

In related news, COO David T. Howton sold 5,072 shares of the firm's stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $28,403.20. Following the transaction, the chief operating officer now directly owns 15,663 shares in the company, valued at $87,712.80. This trade represents a 24.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Alexander Cumbo sold 11,114 shares of Solid Biosciences stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $62,238.40. Following the completion of the transaction, the chief executive officer now directly owns 38,484 shares of the company's stock, valued at approximately $215,510.40. This represents a 22.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,848 shares of company stock worth $155,852 in the last quarter. 13.63% of the stock is owned by corporate insiders.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.